Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
Merck
Colorcon
McKesson

Last Updated: July 3, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021231


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 021231 describes ZOMIG-ZMT, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. Additional details are available on the ZOMIG-ZMT profile page.

The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 021231
Tradename:ZOMIG-ZMT
Applicant:Astrazeneca
Ingredient:zolmitriptan
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021231
Suppliers and Packaging for NDA: 021231
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231 NDA Impax Generics 0115-0691 0115-0691-51 1 BLISTER PACK in 1 CARTON (0115-0691-51) > 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231 NDA Amneal Pharmaceuticals 64896-691 64896-691-49 1 BLISTER PACK in 1 CARTON (64896-691-49) > 2 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength2.5MG
Approval Date:Feb 13, 2001TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength5MG
Approval Date:Sep 17, 2001TE:ABRLD:Yes

Expired US Patents for NDA 021231

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-001 Feb 13, 2001   Start Trial   Start Trial
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-002 Sep 17, 2001   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
McKesson
Boehringer Ingelheim
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.